New Releases from NCBI BookshelfPembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer.​Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer.